Endothelial arginase II responds to pharmacological inhibition by elevation in protein level

Karina Krotova, Jawaharlal M. Patel, Edward R. Block, Sergey Zharikov

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Arginase is an enzyme which converts arginine to ornithine and urea. Recently, arginase has been implicated in many physiological and pathological processes including vascular diseases. Inhibition of arginase activity by pharmacological inhibitors is a useful tool to study the biology of arginases and their possible role in therapy. There are several arginase-specific inhibitors commercially available. Herein, we show that some of these inhibitors lead to an increase in arginase II protein level and activity. These effects should be anticipated when these inhibitors are in use or during the testing of new arginase inhibitors.

Original languageEnglish (US)
Pages (from-to)211-216
Number of pages6
JournalMolecular and cellular biochemistry
Issue number1-2
StatePublished - Oct 2010
Externally publishedYes

Bibliographical note

Funding Information:
Acknowledgments This study was supported in part by National Institutes of Health Grants HL-68607, HL-85133 and VA Merit Review (to J.M.P), as well as Florida DOH Grant 08KN-08-17234 (to K.K.).


  • Arginase
  • Arginase inhibitors
  • Endothelium


Dive into the research topics of 'Endothelial arginase II responds to pharmacological inhibition by elevation in protein level'. Together they form a unique fingerprint.

Cite this